| Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment J Ansari, AR Naqash, R Munker, H El‐Osta, S Master, JD Cotelingam, ... European journal of haematology 97 (1), 9-16, 2016 | 83 | 2016 |
| DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells P Peddi, CW Loftin, JS Dickey, JM Hair, KJ Burns, K Aziz, DC Francisco, ... Free Radical Biology and Medicine 48 (10), 1435-1443, 2010 | 82 | 2010 |
| Induction and processing of complex DNA damage in human breast cancer cells MCF-7 and nonmalignant MCF-10A cells DC Francisco, P Peddi, JM Hair, BA Flood, AM Cecil, PT Kalogerinis, ... Free Radical Biology and Medicine 44 (4), 558-569, 2008 | 79 | 2008 |
| Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library BE Lally, GA Geiger, S Kridel, AE Arcury-Quandt, ME Robbins, ND Kock, ... Cancer research 67 (18), 8791-8799, 2007 | 78 | 2007 |
| Excellent response to chemotherapy post immunotherapy AD Dwary, S Master, A Patel, C Cole, R Mansour, G Mills, N Koshy, ... Oncotarget 8 (53), 91795, 2017 | 66 | 2017 |
| Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of … QD Chu, M Zhou, KL Medeiros, P Peddi, M Kavanaugh, XC Wu BMC cancer 16 (1), 460, 2016 | 57 | 2016 |
| Positive surgical margins contribute to the survival paradox between patients with stage IIB/C (T4N0) and stage IIIA (T1-2N1, T1N2a) colon cancer QD Chu, M Zhou, K Medeiros, P Peddi Surgery 160 (5), 1333-1343, 2016 | 47 | 2016 |
| Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment H El-Osta, K Shahid, GM Mills, P Peddi OncoTargets and therapy, 5101-5116, 2016 | 36 | 2016 |
| Processing of clustered DNA damage in human breast cancer cells MCF-7 with partial DNA-PKcs deficiency P Peddi, DC Francisco, AM Cecil, JM Hair, MI Panayiotidis, ... Cancer letters 269 (1), 174-183, 2008 | 36 | 2008 |
| 212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced … SM Tolaney, A Chan, K Petrakova, S Delaloge, M Campone, H Iwata, ... Annals of Oncology 33, S634-S635, 2022 | 34 | 2022 |
| Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review D Sommerhalder, AM Takalkar, R Shackelford, P Peddi Clinical Case Reports 5 (12), 2121, 2017 | 32 | 2017 |
| Impact of CALGB 9343 trial and sociodemographic variation on patterns of adjuvant radiation therapy practice for elderly women (≥ 70 years) with stage I, estrogen receptor … QD Chu, M Zhou, KL Medeiros, P Peddi, XC Wu Anticancer research 37 (10), 5585-5594, 2017 | 32 | 2017 |
| Influence of facility type on survival outcomes after pancreatectomy for pancreatic adenocarcinoma QD Chu, M Zhou, P Peddi, KL Medeiros, GB Zibari, H Shokouh-Amiri, ... HPB 19 (12), 1046-1057, 2017 | 29 | 2017 |
| Cisplatin, cetuximab, and radiation in locally advanced head and neck squamous cell cancer: a retrospective review P Peddi, R Shi, B Nair, F Ampil, GM Mills, SH Jafri Clinical Medicine Insights: Oncology 9, CMO. S18682, 2015 | 28 | 2015 |
| Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam P Peddi, NE Ajit, G Von Burton, H El-Osta Case Reports 2016, bcr2016217393, 2016 | 16 | 2016 |
| Effect of postmastectomy radiation on survival of AJCC pN2/N3 breast cancer patients Z Shi, P Peddi, G Burton, G Mills, R Shi Anticancer research 36 (1), 261-269, 2016 | 16 | 2016 |
| Follicular dendritic sarcoma masquerading as fibrosing mediastinitis SR Cingam, M Al Shaarani, A Takalkar, P Peddi Case Reports 2017, bcr-2016-218889, 2017 | 13 | 2017 |
| Clinical review: management of adult kasabach-merritt syndrome associated with hemangiomas S Master, D Kallam, H El-Osta, P Peddi J Blood Disord Transfus 8 (5), 397, 2017 | 13 | 2017 |
| Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised … N Harbeck, S Modi, L Pusztai, S Ohno, J Wu, SB Kim, A Yoshida, A Fabi, ... Annals of Oncology, 2025 | 10 | 2025 |
| Iatrogenic constipation from barium blockade: A case report S Pathan, T Benzar, S Master, P Peddi Clinical Case Reports 7 (8), 1562-1564, 2019 | 10 | 2019 |
